



## ADVANCE TAX (Jan - Mar 2012)

All companies are required to pay advance tax in four installments in each financial year. Going by norms laid down by the Income-tax Act, firms are required to pay 15% of their total advance tax in the first quarter (Q1), followed by 30%, 30% and 25% in the next three quarters, respectively. Higher advance tax payments by the companies reflect better result expectation.

Following is the table of advance tax payments by companies in Jan-Mar 2012

### Nifty companies:

Company Name	Jan-Mar 2012 (in cr)	Jan-Mar 2011 (in cr)	Oct-Dec 2011 (in cr)	Change In % (Y-o-Y)	Change In % (Q-o-Q)
ACC	150	170	95	-11.76	57.89
Ambuja Cement	250	170	115	47.06	117.39
Axis Bank	515	550	662	-6.36	-22.21
Bajaj Auto	290	250	450	16.00	-35.56
BPCL	nil	--	--	nil	--
Cipla	80	55	90	45.45	-11.11
Grasim	100	130	100	-23.08	0.00
HDFC	400	340	480	17.65	-16.67
HDFC Bank	600	550	900	9.09	-33.33
Hindalco	150	160	200	-6.25	-25.00
Hindustan Unilever	170	140	300	21.43	-43.33
HPCL	nil	30	nil	nil	--
ICICI Bank	425	450	450	-5.56	-5.56
Kotak Mahindra Bank	120	75	150	60.00	-20.00
Larsen & Toubro	300	300	350	0.00	-14.29
Mahindra & Mahindra	200	300	220	-33.33	-9.09
Reliance Industries	1130	1050	1000	7.62	13.00
Siemens	110	110	70	0.00	57.14
State Bank of India	1650	1500	1730	10.00	-4.62
Tata Consultancy	550	200	550	175.00	0.00
Tata Motors	50	50	80	0.00	-37.50
Tata Power	90	40	80	125.00	12.50
Tata Steel	900	950	1100	-5.26	-18.18

**Non-Nifty companies:**

Company Name	Jan-Mar 2012 (in cr)	Jan-Mar 2011 (in cr)	Oct-Dec 2011 (in cr)	Change In % (Y-o-Y)	Change In % (Q-o-Q)
Asian Paints	110	90	130	22.22	-15.38
Bank of Baroda	400	400	550	0.00	-27.27
Bank of India	400	320	--	25.00	--
Castrol	50	60	--	-16.67	--
Colgate Palmolive	37	25	40	48.00	-7.50
Dena Bank	110	55	--	100.00	--
Godrej Consumer	40	10	40	300.00	0.00
GSK Consumer	60	55	--	9.09	--
IDBI Bank	200	210	--	-4.76	--
IndusInd Bank	90	100	120	-10.00	-25.00
IOC	nil	--	--	nil	--
LIC Housing	90	100	90	-10.00	0.00
Lupin	60	55	44	9.09	36.36
Novartis	18	17	20	5.88	-10.00
Nuclear Power Corp	110	120	165	-8.33	-33.33
Oracle Financial Serv	70	55	45	27.27	55.56
Pfizer	25	30	30	-16.67	-16.67
Pidilite	30	30	30	0.00	0.00
Piramal Healthcare	nil	--	--	--	--
UltraTech	170	120	210	41.67	-19.05
Union Bank of India	200	70	220	185.71	-9.09
YES Bank	110	100	160	10.00	-31.25

**Others:**

Company Name	Jan-Mar 2012 (in cr)	Jan-Mar 2011 (in cr)	Oct-Dec 2011 (in cr)	Change In % (Y-o-Y)	Change In % (Q-o-Q)
Citibank	500	450	400	11.11	25.00
GIC	nil	70	--	nil	nil
HSBC	450	450	420	0.00	7.14
LIC	970	930	1200	4.30	-19.17

Source- NW18

## Contact

SMS: 'Arihant' to 56677

## Website

[www.arihantcapital.com](http://www.arihantcapital.com)

## Email Id

[research@arihantcapital.com](mailto:research@arihantcapital.com)

**Disclaimer:** This document has been prepared by Arihant Capital Markets Limited (hereinafter called as Arihant) and its subsidiaries and associated companies. This document does not constitute an offer or solicitation for the purchase and sale of any financial instrument by Arihant. Receipt and review of this document constitutes your agreement not to circulate, redistribute, retransmit or disclose to others the contents, opinions, conclusion, or information contained herein. This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. All recipients of this material should before dealing and or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice. The investments discussed in this material may not be suitable for all investors. The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material. Arihant Capital Markets Ltd (including its affiliates) or its officers, directors, personnel and employees, including persons involved in the preparation or issuance of this material may; (a) from time to time, have positions in, and buy or sell or (b) be engaged in any other transaction and earn brokerage or other compensation in the financial instruments/products discussed herein or act as advisor or lender/borrower in respect of such securities/financial instruments/products or have other potential conflict of interest with respect to any recommendation and related information and opinions. The said persons may have acted upon and/or in a manner contradictory with the information contained here and may have a position or be otherwise interested in the investment referred to in this document before its publication. The user of this report assumes the entire risk of any use made of this data / Report. Arihant especially states that it has no financial liability, whatsoever, to the users of this Report.

Arihant is Forbes Asia's '200 Best under a Billion' Company  
'Best Emerging Commodities Broker' awarded by UTV Bloomberg

**ARIHANT capital markets Ltd.**3<sup>rd</sup> Floor Krishna Bhavan, 67 Nehru Road, Vile Parle (E), Mumbai – 400057

T. 022-42254800 F. 022-42254880